PMID- 26590369
OWN - NLM
STAT- MEDLINE
DCOM- 20171006
LR  - 20220318
IS  - 1520-7560 (Electronic)
IS  - 1520-7552 (Linking)
VI  - 32
IP  - 6
DP  - 2016 Sep
TI  - Serum uric acid level as an indicator for CKD regression and progression in 
      patients with type 2 diabetes mellitus-a 4.6-year cohort study.
PG  - 557-64
LID - 10.1002/dmrr.2768 [doi]
AB  - BACKGROUND: To investigate the association of serum uric acid level with renal 
      function change in patients with type 2 diabetes mellitus (T2DM). METHODS: T2DM 
      patients who had been followed-up for at least 3 years were included. 
      Participants were categorized into stable, progression, or regression groups 
      according to their change in chronic kidney disease (CKD) stage. During the 
      follow-up period, all numeric values of metabolic factors, including the uric 
      acid level and the medication possession rate, were calculated in order to 
      investigate their associations with CKD development. Multivariate Cox regression 
      analyses were used to identify independent factors associated with change in CKD. 
      RESULTS: A total of 2367 T2DM patients were enrolled in this study and 
      followed-up for a mean of 4.6 years. The numbers of patients in the stable, 
      progression and regression groups were 1133 (47.9%), 487 (20.6%), and 747 
      (31.5%), respectively. The progression group had the highest serum uric acid 
      level (6.9 +/- 1.8 mg/dL), and the regression group had the lowest uric acid level 
      (5.4 +/- 1.5 mg/dL). In addition, we found that the serum uric acid level was an 
      independent factor associated with CKD progression when the value exceeded 
      6.3 mg/dL. A lower uric acid level could be beneficial for CKD improvement in 
      T2DM patients with stage 3-5 CKD. CONCLUSIONS: Our data indicated that the serum 
      uric acid level is associated with CKD regression and progression and suggested 
      that a high normal serum uric acid level should be closely monitored in patients 
      with T2DM. Copyright (c) 2015 John Wiley & Sons, Ltd.
CI  - Copyright (c) 2015 John Wiley & Sons, Ltd.
FAU - Chang, Yu-Hung
AU  - Chang YH
AD  - Lee's Endocrinology Clinic, Pingtung, Taiwan.
FAU - Lei, Chen-Chou
AU  - Lei CC
AD  - Lee's Endocrinology Clinic, Pingtung, Taiwan.
FAU - Lin, Kun-Chen
AU  - Lin KC
AD  - Lee's Endocrinology Clinic, Pingtung, Taiwan.
FAU - Chang, Dao-Ming
AU  - Chang DM
AD  - Lee's Endocrinology Clinic, Pingtung, Taiwan.
FAU - Hsieh, Chang-Hsun
AU  - Hsieh CH
AD  - Division of Endocrinology and Metabolism, Department of Internal Medicine, 
      National Defense Medical Center, Tri-Service General Hospital, Taipei, Taiwan.
FAU - Lee, Yau-Jiunn
AU  - Lee YJ
AD  - Lee's Endocrinology Clinic, Pingtung, Taiwan.
LA  - eng
PT  - Journal Article
DEP - 20151222
PL  - England
TA  - Diabetes Metab Res Rev
JT  - Diabetes/metabolism research and reviews
JID - 100883450
RN  - 0 (Biomarkers)
RN  - 268B43MJ25 (Uric Acid)
SB  - IM
MH  - Biomarkers/*blood
MH  - Cohort Studies
MH  - Diabetes Mellitus, Type 2/*complications
MH  - Disease Progression
MH  - Female
MH  - Glomerular Filtration Rate
MH  - Humans
MH  - Hyperuricemia/blood/*diagnosis/etiology
MH  - Male
MH  - Middle Aged
MH  - Prognosis
MH  - Renal Insufficiency, Chronic/blood/*diagnosis/etiology
MH  - Risk Factors
MH  - Time Factors
MH  - Uric Acid/*blood
OTO - NOTNLM
OT  - chronic kidney disease
OT  - diabetic nephropathy
OT  - type 2 diabetes mellitus
OT  - uric acid
EDAT- 2015/11/22 06:00
MHDA- 2017/10/07 06:00
CRDT- 2015/11/22 06:00
PHST- 2015/06/19 00:00 [received]
PHST- 2015/09/27 00:00 [revised]
PHST- 2015/10/28 00:00 [accepted]
PHST- 2015/11/22 06:00 [entrez]
PHST- 2015/11/22 06:00 [pubmed]
PHST- 2017/10/07 06:00 [medline]
AID - 10.1002/dmrr.2768 [doi]
PST - ppublish
SO  - Diabetes Metab Res Rev. 2016 Sep;32(6):557-64. doi: 10.1002/dmrr.2768. Epub 2015 
      Dec 22.